Lartruvo▼ (olaratumab): withdrawal of the EU marketing authorisation due to lack of efficacy

Source:
GOV UK
Publisher:
Medicines and Healthcare products Regulatory Agency
Publication date:
19 June 2019

Abstract

The ANNOUNCE study failed to show clinical efficacy for olaratumab in its current indication of advanced soft tissue sarcoma and the benefit risk balance is therefore now considered negative.